Comprehensive Medicinal Chemistry II

1st Edition

Volume 7: THERAPEUTIC AREAS II: Cancer, Infectious Diseases, Inflammation & Immunology and Dermatology


  • Jake Plattner
  • Manoj Desai
    • Print ISBN 9780080445205


    This volume reviews important therapeutic areas, their causes, diagnosis, experimental disease models, treatments, unmet medical needs and future research areas. Areas covered include Cancer (biology, chemotherapy, mechanism & target approaches), Infectious Diseases (viral [herpes, HIV], fungal, bacterial & parasitic), Inflammation & Immunology (arthritis, asthma) and Dermatology (acne, psoriasis). For each area experts examine the key roles that medicinal chemistry and pharmacology play in reviving the fortunes of the drug discovery process and developing new treatments. Ideal for students and researchers in chemistry, biochemistry, medicinal chemistry and pharmacology and scientists working in the pharmaceutical industries.

    Key Features

    * valuable content available May 2009 as an individual volume
    * separate volumes will appeal to a wider chemistry, biochemistry and medicinal audience
    * priced for individual researcher as well as library purchase


    For students and researchers in chemistry, biochemistry, medicinal chemistry and pharmacology and scientists working in the pharmaceutical industries.

    Table of Contents

    Volume 7 Therapeutic Areas II: Cancer, Infectious Diseases, Inflammation & Immunology and Dermatology
    Anti Cancer
    7.01 Cancer Biology
    7.02 Principles of Chemotherapy and Pharmacology
    7.03 Antimetabolites
    7.04 Microtubule Targeting Agents
    7.05 Deoxyribonucleic Acid Topoisomerase Inhibitors
    7.06 Alkylating and Platinum Antitumor Compounds
    7.07 Endocrine Modulating Agents
    7.08 Kinase Inhibitors for Cancer
    7.09 Recent Development in Novel Anticancer Therapies
    Anti Viral
    7.10 Viruses and Viral Diseases
    7.11 Deoxyribonucleic Acid Viruses: Antivirals for Herpesviruses and Hepatitis B Virus
    7.12 Ribonucleic Acid Viruses: Antivirals for Human Immunodeficiency Virus
    7.13 Ribonucleic Acid Viruses: Antivirals for Influenza A and B, Hepatitis C Virus, and Respiratory Syncytial Virus
    Anti Fungal
    7.14 Fungi and Fungal Disease
    7.15 Major Antifungal Drugs
    Anti Bacterials
    7.16 Bacteriology, Major Pathogens, and Diseases
    7.17 β-Lactam Antibiotics
    7.18 Macrolide Antibiotics
    7.19 Quinolone Antibacterial Agents
    7.20 The Antibiotic and Nonantibiotic Tetracyclines
    7.21 Aminoglycosides Antibiotics
    7.22 Anti-Gram Positive Agents of Natural Product Origins
    7.23 Oxazolidinone Antibiotics
    7.24 Antimycobacterium Agents
    7.25 Impact of Genomics-Emerging Targets for Antibacterial Therapy
    Drugs for Parasitic Infections
    7.26 Overview of Parasitic Infections
    7.27 Advances in the Discovery of New Antimalarials
    7.28 Antiprotozoal Agents (African Trypanosomiasis, Chagas Disease, and Leishmaniasis)
    I and I Diseases
    7.29 Recent Advances in Inflammatory and Immunological Diseases: Focus on Arthritis Therapy
    7.30 Asthma and Chronic Obstructive Pulmonary Disease
    7.31 Treatment of Transplantation Rejection and Multiple Sclerosis
    7.32 Overview of Derma


    No. of pages:
    © 2007
    Elsevier Science
    Print ISBN:

    About the authors

    Manoj Desai

    Dr. Manoj Desai began his career in the pharmaceutical industry at Pfizer Inc, Central Research Division, Groton, CT (1986-1994) before moving to Chiron Corporation (1994-2003) as Director of medicinal chemistry; he was promoted to Vice President, lead discovery and medicinal chemistry (2000). In October 2003, he was appointed Vice President of medicinal chemistry at Gilead Sciences. At Pfizer, he was responsible for the medicinal chemistry efforts that lead to the discovery of oral Substance P antagonist CP-99994 which became the basis for the discovery of the new anti-emetics. At Chiron he formulated macrobead technology for the synthesis and screening of compound libraries for HTS and built the medicinal chemistry department with focus on kinase inhibitors. At Gilead, he was an active proponent to develop a pharmacoenhancer devoid of antiviral activity to improve the pharmacokinetics of integrase inhibitor elvitegravir. These efforts led to the discovery of Cobicistat which is one of components of StribildTM that was approved by FDA in August 2012 for the treatment of HIV infection. He is co-inventor on patents of Cobicistat (US 8,148,374), StribildTM and Ledipasvir (US 8,273,341; Phase III). Furthermore, his group at Gilead has advanced numerous compounds into clinical development for the treatment of antiviral diseases, cancer and cardiovascular diseases. Dr. Desai obtained Ph.D. in organic chemistry from the M.S. University of Baroda in 1981 working with Dr. Sukh Dev and then carried out post-doctoral fellowships at Purdue University working with Professor Herbert C. Brown (19981-1983) and at Harvard University with Professor Elias J. Corey (1983-1986). During his postdoctoral studies, he worked on natural product isolation, development of asymmetric synthetic methods using organoboranes and total synthesis of complex natural products such as retigeranic acid, -trans bergamotene and ginkgolide B. He has co-authored >60 publications in peer revie